GlassScriptPhysician profile
Brooke A Jackson
NPI 1508905662
$742.07
in general payments reported to CMS, 2019-2025
19 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $150 · 2024: $440 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $742.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $742.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $130.23 | 2023-2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $98.55 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Eisai INC. | $89.14 | 2023-2024 | |
| Novo Nordisk INC | $62.88 | 2024 | Ozempic, Rybelsus |
| Lilly USA, LLC | $60.15 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $45.74 | 2023-2024 | |
| Amgen INC. | $31.38 | 2024-2025 | Evenity, Prolia, Prolia |
| Pfizer INC. | $30.00 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $27.68 | 2024-2025 | Voquezna |
| Depuy Synthes Sales INC. | $23.03 | 2024 | Monovisc |
| Astellas Pharma US INC | $21.37 | 2025 | Veozah |
| Ironwood Pharmaceuticals, INC | $17.44 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.99 | 2024 | Jardiance |
| Tris Pharma INC | $15.27 | 2025 | Dyanavel Xr |
| Genzyme Corporation | $15.23 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.87 | 2024 | Xifaxan |
| Exact Sciences Corporation | $14.65 | 2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $13.78 | 2023 | |
| Sumitomo Pharma America, INC. | $13.69 | 2024 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.